This page is updated frequently with new Kinetics-related patent applications.
| In vitro pharmacokinetics/pharmacodynamics bellows perfusion system for enhancing effectiveness of cancer chemotherapy|
Provided herein is a continuous cell perfusion model system that provides useful pharmacokinetic and pharmacodynamic information on the application of new drugs or combinations of various agents in vitro to human cancer cell lines. Also provided are methods of using this system to individualize cancer treatment..
|Metal hydride alloys with improved rate performance|
Methods of preparing improved metal hydride alloy materials are provided. The alloys include a mixture of at least four of vanadium, titanium, nickel, chromium, and iron.
California Institute Of Technology
|Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy|
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an ad moiety attached to the c-terminal end of each antibody light chain. The complexes further comprise effector moities attached to ddd moieties.
Ibc Pharmaceuticals, Inc.
|Infusion pump drug delivery profiles, systems, and methods|
Embodiments relate generally to drug delivery infusion profiles that can be transferred and executed on infusion pumps without the need for loading new firmware. Particularly, embodiments relate to integrating and/or editing delivery profiles for execution infusion systems.
Smiths Medical Asd, Inc.
|Poly(vinyl benzoate) nanoparticles for molecular delivery|
The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using pluronic f68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases.
University Of South Florida
|Enhancing the physical properties of semi-crystalline polymers via solid-state shear pulverization|
Solid-state shear pulverization of semi-crystalline polymers and copolymers thereof and related methods for enhanced crystallization kinetics and physical/mechanical properties.. .
|Paired laser and electrokinetic separation, manipulation, and analysis device|
The combined value of integrating optical forces and electrokinetics allows for the pooled separation vectors of each to be applied, providing for separation based on combinations of features such as size, shape, refractive index, charge, charge distribution, charge mobility, permittivity, and deformability. The interplay of these separation vectors allow for the selective manipulation of analytes with a finer degree of variation.
The Government Of The United States Of America, As Represented By The Secretary Of The Navy
|Catalytic effects of oxygen carrier based chemicl-looping reforming of ch4 with co2|
The invention relates to ceo2 and la2o3 for catalyzing fe2o3—al2o3 based chemical-looping reforming of ch4 with co2 (cl-drm). The reaction performance of all the composite oxygen carriers was evaluated in a fixed-bed reactor at atmospheric pressure condition.
University Of Wyoming
|All natural, non-toxic sublingual drug delievery systems|
All natural non-toxic sublingual delivery systems improve absorption and onset profiles for numerous actives, along with bioavailability and pharmacokinetics results that are better than expected for families of moieties compounds and legacy-patented formulations.. .
|Particle based immunoassay with alternating current electrokinetics|
Disclosed are methods, devices and systems of an immunoassay using an alternate current electrokinetic platform. Also disclosed are methods of separating and detecting analytes from a sample using the disclosed methods..
Biological Dynamics, Inc.
Parenteral formulations of dopamine agonists
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics..
Process for dyeing keratin materials using powder from indigo-producing plants and alkaline agent(s)
The invention relates (i) to a process for dyeing keratin materials, in particular keratin fibres, preferably human keratin fibres such as the hair, using i) indigo-producing plant powder, ii) at least one alkaline agent as a post-treatment, preferably an alkali metal or alkaline-earth metal (bi) carbonate and iii) optionally a chemical oxidizing agent such as hydrogen peroxide or a hydrogen peroxide-generating system in co-treatment with i), and it being understood that the composition comprising the alkaline agent(s) is at a ph inclusively between 7.5 and 11.5; and (ii) to the use iii) of alkaline agent(s) for fixing the blue colour of and/or for improving the dyeing kinetics of keratin materials dyed with indigo.. .
Pharmacokinetics of iontophoretic sumatriptan administration
Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.. .
Teva Pharmaceuticals International Gmbh
Sphingosine kinase type 1 inhibitors and uses thereof
Provided are inhibitors of sphingosine kinase type i that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (gbm)..
Virginia Commonwealth University
Yeast strains for producing first-generation ethanol
The present invention concerns yeast strains that have improved properties relative to the specialised strains that are used in the production of first-generation ethanol. In particular, the strains of the invention have an increased ethanol yield, a lower production of glycerol and ethanol production kinetics that are similar or slightly slower than standard strain d1b.
Lesaffre Et Compagnie
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
The present invention provides ligand-drug conjugates comprising a peg unit in a parallel orientation to the drug unit. The invention provides inter alia, ligand-drug conjugates (ldcs), methods of preparing and using them, and intermediates thereof.
Seattle Genetics, Inc.
Controlled release and taste masking oral pharmaceutical composition
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. A structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices.
Cosmo Technologies Limited
High performance knee prostheses
Knee prostheses that more faithfully replicate the structure and function of the human knee joint in order to provide, among other benefits: greater flexion of the knee in a more natural way by promoting or accommodating internal tibial rotation, replication of the natural screw home mechanism, and controlled articulation of the tibia and femur respective to each other in a natural way. Such prostheses may include an insert component disposed between a femoral component and a tibial component, the insert component featuring, among other things, a reversely contoured posterolateral bearing surface that helps impart internal rotation to the tibia as the knee flexes.
The Trustees Of The University Of Pennsylvania
Population pharmacokinetics tools and uses thereof
The present invention is directed to computer based pharmacokinetics systems, such as. Web-based pharmacokinetics systems, and their use to predict a dose and a dosing interval for a patient in need of a clotting factor therapy..
Biogen Ma Inc.
Solid form of abiraterone acetate
Combinations of (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acidare useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.. .
Method of making modified activated carbon
An activated carbon substrate which is pre-treated to make an exposed surface of the activated carbon substrate substantially hydrophilic, coated with a carbon precursor to form a coated activated carbon, and then the coated activated carbon substrate is heated to carbonize the carbon precursor to from the modified activated carbon. The modified activated carbon comprises a uniform porous carbon membrane formed on an exposed surface of the activated carbon substrate.
Philip Morris Usa Inc.
Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting cyp3a4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by cyp3a4..
Merck Sharp & Dohme Corp.
Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting cyp3a4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by cyp3a4..
Merck Sharp & Dohme Corp.
Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (svcam) and/or soluble mucosal addressin cell adhesion molecule (smadcam) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (pk/pd) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation..
Power generation systems and methods regarding same
A solid fuel power source that provides at least one of thermal and electrical power such as direct electricity or thermal to electricity is further provided that powers a power system comprising (i) at least one reaction cell for the catalysis of atomic hydrogen to form hydrinos, (ii) a chemical fuel mixture comprising at least two components chosen from: a source of h20 catalyst or h20 catalyst; a source of atomic hydrogen or atomic hydrogen; reactants to form the source of h20 catalyst or h20 catalyst and a source of atomic hydrogen or atomic hydrogen; one or more reactants to initiate the catalysis of atomic hydrogen; and a material to cause the solid fuel to be highly conductive, (iii) at least one set of electrodes that confine the fuel and an electrical power source that provides a short burst of low-voltage, high-current electrical energy to initiate rapid kinetics of the hydrino reaction and an energy gain due to forming hydrinos, (iv) a product recovery systems such as a condenser (v) a reloading system, (vi) at least one of hydration, thermal, chemical, and electrochemical systems to regenerate the fuel from the reaction products, (vii) a heat sink that accepts the heat from the power-producing reactions, (viii) a power conversion system that may comprise a direct plasma to electric converter such as a plasmadynamic converter, magnetohydrodynamic converter, electromagnetic direct (crossed field or drift) converter, direct converter, and charge drift converter or a thermal to electric power converter such as a rankine or brayton-type power plant.. .
Brilliant Light Power, Inc.
Aerosol fluoroquinolone formulations for improved pharmacokinetics
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract..
Raptor Pharmaceuticals Inc.
Method for determining interaction kinetics with rapid dissociation
The invention relates to a method for determining interaction kinetics for an analyte. The method comprises first contacting a solution containing the analyte with immobilized ligand, or analogue thereof, immobilized on an optical sensor surface; monitoring the binding of the analyte to the immobilized ligand or analogue, wherein the binding is measured as a resulting change in a property of the surface; and automatically determining the interaction kinetics, which determining step includes first defining parts of the dissociation phase that contains kinetic information for fitting.
Ge Healthcare Bio-sciences Ab
A fuel injector includes fixed metal components, in particular an injector body, a solenoid actuator equipped with a retaining spring that holds a control valve stem, a control valve body including a seat for the control valve stem, a spacer between the body of the control valve and an injection nozzle, a control chamber, and an injection needle seat. The fuel injector also includes movable metal components, in particular the control valve stem and an armature thereof and an injection needle.
Delphi International Operations Luxembourg S.À R.l.
Composition of excipients and pharmaceutical forms with sustained release and increased bioavailability of antibacterial drugs, anticoccidial drugs and other drugs for commercial poultry and pigs
The invention relates to a composition of excipients and pharmaceutical forms of sustained release and increased drug bioavailability for poultry and pigs and to a method of producing the same, said composition comprises: pharmaceutically active agents, bioavailability promoting agents, polymers for prolonged release of the drug, colouring agents, and flavouring agents. The composition of excipients and pharmaceutical forms of the invention optimizes the dosing of the drug dosage and generates resistant strains of bacteria by optimizing the ratio between pharmacokinetics/pharmacodynamics of drugs.
Universidad Nacional AutÓnoma De MÉxico
Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphilphilic molecules
Aspects of the invention relate to methods for measuring the binding constant of a lipophilic or amphiphilic molecule acceptor for a lipophilic or amphiphilic molecule. Methods involve rapid, cell-free competition assays including a labeled lipophilic or amphiphilic molecule and nanoparticle..
Calcium-magnesium-alumino-silicate resistant thermal barrier coatings
A method for forming a coating system on a component includes depositing a reactive layer with predetermined cmas reaction kinetics on at least a portion of a thermal baffler coating. The method also includes activating the reactive layer with a scanning laser.
United Technologies Corporation
Sorbic acid ester containing coatings composition
The present invention is a composition comprising a solution or a dispersion of polymer particles, a sorbate ester or sorbamide curing agent, and a cure modulating additive for the curing agent. The curing agent is a sorbic acid ester or a sorbamide and the cure modulating agent is a reagent capable of accelerating or attenuating the rate of cure of the curing agent.
Rohm And Haas Company
Disubstituted maleic anhydrides with altered kinetics of ring closure
We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules.
Arrowhead Madison Inc.
Spraying device for quickly forming gas hydrates
A spraying device for quickly forming gas hydrates, includes a stable gas supply system, a saturated solution preparation system, a gas-liquid mixed sprayer, a temperature control system and a data collecting and processing system. Pressure atomization is achieved at a high atomization speed and the atomized fog drops are uniformly distributed within a scale range of 5-10 microns to form a gas-in-water contact mode, so as to effectively increase a gas-water contact superficial area and significantly shorten the induction time of forming the gas hydrates.
Guangzhou Institute Of Energy Conversion, Chinese Academy Of Sciences
Polymerase compositions and methods
Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions.
Life Technologies Corporation
Extensible infusion devices and related methods
Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device to deliver fluid to a user in accordance with an operating mode involves identifying a fluid type associated with the fluid currently onboard the infusion device from among a plurality of possible fluid types that is different from a previous type of fluid previously onboard the infusion device.
Medtronic Minimed, Inc.
Vortex-induced silk fibroin gelation for encapsulation and delivery
The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of β-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention provides a silk fibroin gel that may be reversibly shear-thinned, enabling the use of these approach for precise control of silk self-assembly, both spatially and temporally.
Trustees Of Tufts College
High performance knee prosthesis
Knee prostheses featuring components that more faithfully replicate the structure and function of the human knee joint in order to provide, among other benefits: greater flexion of the knee in a more natural way by promoting or at least accommodating internal tibial rotation in a controlled way, replication of the natural screw home mechanism, and controlled articulation of the tibia and femur respective to each other in a more natural way. In a preferred embodiment, such prostheses include an insert component disposed between a femoral component and a tibial component, the insert component preferably featuring among other things a reversely contoured posterolateral bearing surface that helps impart internal rotation to the tibia as the knee flexes.
The Trustees Of The University Of Pennsylvania
Implantable devices and methods for evaluation of active agents
Devices for the local delivery of microdose amounts of one or more active agents, alone or in combination, in one or more dosages, to selected tissue of a patient are described. The devices generally include multiple microwells arranged on or within a support structure and contain one or more active agents, alone or in combination, in one or more dosages and/or release pharmacokinetics.
Massachusetts Institute Of Technology
Tunable covalently crosslinked hydrogels and methods of making the same
The present invention provides, among other things, a elastomeric biomaterial having enzymatically cross-linked amino acid phenolic side chains to generate highly elastic hydrogels. Materials are characterized by tunable mechanical properties, gelation kinetics and swelling properties of these new protein polymers.
Trustees Of Tufts College
Environmentally sensitive compositions
An environmentally sensitive membrane binding polypeptide, ph (low)-sensitive membrane peptide (phlip) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.. .
Anti-c5 antibodies having improved pharmacokinetics
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the c5b-9 tcc) and c5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human..
Alexion Pharmaceuticals, Inc.
Designed repeat proteins binding to serum albumin
New designed repeat proteins with binding specificity for serum albumin are described, as well as nucleic acids encoding such serum albumin binding proteins, pharmaceutical compositions comprising such proteins, the use of such proteins to modify the pharmacokinetics of therapeutic relevant polypeptides and the use of such proteins in the treatment of diseases. The repeat proteins of the invention have a substantially increased half-life in plasma compared to proteins not binding serum albumin..
Molecular Partners Ag
Evolution of bond-forming enzymes
Strategies, systems, methods, reagents, and kits for the directed evolution of bond-forming enzymes are provided herein. Evolution products, for example, evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are also provided herein, as are methods for using such evolved bond-forming enzymes.
President And Fellows Of Harvard College
Antibodies with modified affinity to fcrn that promote antigen clearance
The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human fcrn-binding activity at the plasma ph and a lower antigen-binding activity at the early endosomal ph than at the plasma ph; such antibodies can increase the number of antigens to which a single antibody molecule can bind; the reduction of antigen in plasma can be facilitated by administering such an antibody; and antibody pharmacokinetics can be improved by using such antibodies.. .
Voxel-resolution myocardial blood flow analysis
A myocardial blood flow analysis scan includes incorporating a pharmacological kinetic model with the standard factor analysis model where each time activity curve is assumed to be a linear combination of factor curves. Pharmacological kinetics based factor analysis of dynamic structures (k-fads-ii) model can be applied, whereby estimating factor curves in the myocardium can be physiologically meaningful is provided.
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
Auspex Pharmaceuticals, Inc.